4//SEC Filing
Paggiarino Dario A. 4
Accession 0001562180-24-000808
CIK 0001314102other
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 4:53 PM ET
Size
20.3 KB
Accession
0001562180-24-000808
Insider Transaction Report
Form 4
Paggiarino Dario A.
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-01-26$25.41/sh−51$1,296→ 85,779 total - Exercise/Conversion
Common Stock
2024-01-26$12.90/sh+15,609$201,356→ 52,114 total - Exercise/Conversion
Common Stock
2024-01-26$13.13/sh+51$670→ 52,165 total - Sale
Common Stock
2024-01-26$25.41/sh−15,609$396,572→ 70,170 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−15,609→ 1,026 totalExercise: $12.90Exp: 2030-02-28→ Common Stock (15,609 underlying) - Sale
Common Stock
2024-01-26$25.77/sh−33,665$867,672→ 36,505 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−33,665→ 17,588 totalExercise: $13.13Exp: 2031-02-09→ Common Stock (33,665 underlying) - Exercise/Conversion
Common Stock
2024-01-26$13.13/sh+33,665$442,021→ 85,830 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-26−51→ 51,253 totalExercise: $13.13Exp: 2031-02-09→ Common Stock (51 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.62. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
- [F4]The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001574261
Filing Metadata
- Form type
- 4
- Filed
- Jan 29, 7:00 PM ET
- Accepted
- Jan 30, 4:53 PM ET
- Size
- 20.3 KB